<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Maternal medication use in rheumatic diseases</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Maternal medication use in rheumatic diseases</h1>
<div class="graphic"><div class="figure"><div class="ttl">Maternal medication use in rheumatic diseases</div><div class="cntnt"><table cellspacing="0"><colgroup span="4" width="25%"></colgroup> <tbody> <tr class="border_bottom_thick"> <td colspan="4"><strong>Key:</strong> <ul class="none"> <li><span class="primarybox_key highlight_green_text"> </span><span class="large_checkmark">++</span> Strongly recommend</li> <li><span class="primarybox_key highlight_lght_green_text"> </span><span class="large_checkmark">+</span>     Conditionally recommend</li> <li><span class="primarybox_key highlight_lght_red_text"> </span><span class="large_checkmark">×</span>     Conditionally recommend against</li> <li><span class="primarybox_key highlight_red_text"> </span><span class="large_checkmark">××</span> Strongly recommend against</li> </ul> </td> </tr> <tr class="border_bottom_thick"> <td colspan="4"> </td> </tr> <tr class="divider_bottom"> <td class="subtitle1">Medication</td> <td class="subtitle1">Pre-conception</td> <td class="subtitle1">During pregnancy</td> <td class="subtitle1">Breastfeeding</td> </tr> <tr> <td colspan="4"><strong>Conventional medications</strong></td> </tr> <tr> <td class="indent1">Hydroxychloroquine</td> <td class="highlight_green_text"><span class="large_checkmark">++</span></td> <td class="highlight_green_text"><span class="large_checkmark">++</span></td> <td class="highlight_green_text"><span class="large_checkmark">++</span></td> </tr> <tr> <td class="indent1">Sulfasalazine</td> <td class="highlight_green_text"><span class="large_checkmark">++</span></td> <td class="highlight_green_text"><span class="large_checkmark">++</span></td> <td class="highlight_green_text"><span class="large_checkmark">++</span></td> </tr> <tr> <td class="indent1">Colchicine</td> <td class="highlight_green_text"><span class="large_checkmark">++</span></td> <td class="highlight_green_text"><span class="large_checkmark">++</span></td> <td class="highlight_green_text"><span class="large_checkmark">++</span></td> </tr> <tr> <td class="indent1">Azathioprine, 6-mercaptopurine</td> <td class="highlight_green_text"><span class="large_checkmark">++</span></td> <td class="highlight_green_text"><span class="large_checkmark">++</span></td> <td class="highlight_lght_green_text"> <p class="large_checkmark">+</p> Low transfer </td> </tr> <tr> <td class="indent1">Prednisone</td> <td class="highlight_lght_green_text"> <p class="large_checkmark">+</p> Taper to &lt;20 mg/day by adding pregnancy-compatible immunosuppressants </td> <td class="highlight_lght_green_text"> <p class="large_checkmark">+</p> Taper to &lt;20 mg/day by adding pregnancy-compatible immunosuppressants </td> <td class="highlight_lght_green_text"> <p class="large_checkmark">+</p> After a dose of &gt;20 mg, delay breastfeeding for 4 hours </td> </tr> <tr> <td class="indent1">Cyclosporine, tacrolimus</td> <td class="highlight_lght_green_text"> <p class="large_checkmark">+</p> Monitor blood pressure </td> <td class="highlight_lght_green_text"> <p class="large_checkmark">+</p> Monitor blood pressure </td> <td class="highlight_lght_green_text"> <p class="large_checkmark">+</p> Low transfer </td> </tr> <tr class="divider_bottom"> <td class="indent1">Nonsteroidal antiinflammatory drugs (cyclooxygenase 2 inhibitors not preferred)</td> <td class="highlight_lght_green_text"> <p class="large_checkmark">+</p> Discontinue if the woman is having difficulty conceiving </td> <td class="highlight_lght_green_text"> <p class="large_checkmark">+</p> Continue in first and second trimesters; discontinue in third trimester </td> <td class="highlight_lght_green_text"> <p class="large_checkmark">+</p> Ibuprofen preferred </td> </tr> <tr> <td colspan="4"><strong>Tumor necrosis factor inhibitors (tumor necrosis factor inhibitors are considered compatible with pregnancy)</strong></td> </tr> <tr> <td class="indent1">Certolizumab</td> <td class="highlight_green_text"><span class="large_checkmark">++</span></td> <td class="highlight_green_text"><span class="large_checkmark">++</span></td> <td class="highlight_green_text"><span class="large_checkmark">++</span></td> </tr> <tr class="divider_bottom"> <td class="indent1">Infliximab, etanercept, adalimumab, golimumab</td> <td class="highlight_lght_green_text"> <p class="large_checkmark">+</p> Continue through conception </td> <td class="highlight_lght_green_text"> <p class="large_checkmark">+</p> Continue in first and second trimesters; discontinue in third trimester several half-lives prior to delivery </td> <td class="highlight_green_text"><span class="large_checkmark">++</span></td> </tr> <tr class="divider_bottom"> <td><strong>Rituximab</strong></td> <td class="highlight_lght_green_text"> <p class="large_checkmark">+</p> Discontinue at conception </td> <td class="highlight_lght_green_text"> <p class="large_checkmark">+</p> Life-/organ-threatening disease </td> <td class="highlight_green_text"><span class="large_checkmark">++</span></td> </tr> <tr> <td colspan="4"><strong>Other biologics (limited safety data; limited transfer in early pregnancy but high transfer in second half of pregnancy)</strong></td> </tr> <tr class="divider_bottom"> <td class="indent1">Anakinra, belimumab, abatacept, tocilizumab, secukinumab, ustekinumab</td> <td class="highlight_lght_green_text"> <p class="large_checkmark">+</p> Discontinue at conception </td> <td class="highlight_lght_red_text"> <p class="large_checkmark">×</p> Discontinue during pregnancy </td> <td class="highlight_lght_green_text"> <p class="large_checkmark">+</p> Expect minimal transfer due to large molecular size, but no available data </td> </tr> <tr> <td colspan="4"><strong>Not compatible with pregnancy</strong></td> </tr> <tr> <td class="indent1">Methotrexate</td> <td class="highlight_red_text"> <p class="large_checkmark">××</p> Stop 1-3 months prior to conception </td> <td class="highlight_red_text"> <p class="large_checkmark">××</p> Stop and give folic acid 5 mg/day </td> <td class="highlight_lght_red_text"> <p class="large_checkmark">×</p> Limited data suggest low transfer </td> </tr> <tr> <td class="indent1">Leflunomide</td> <td class="highlight_red_text"> <p class="large_checkmark">××</p> Cholestyramine washout if detectable levels </td> <td class="highlight_red_text"> <p class="large_checkmark">××</p> Stop and give cholestyramine washout </td> <td class="highlight_red_text"><span class="large_checkmark">××</span></td> </tr> <tr> <td class="indent1">Mycophenolate mofetil and mycophenolic acid</td> <td class="highlight_red_text"> <p class="large_checkmark">××</p> Stop &gt;6 weeks prior to conception to assess disease stability </td> <td class="highlight_red_text"><span class="large_checkmark">××</span></td> <td class="highlight_red_text"><span class="large_checkmark">××</span></td> </tr> <tr> <td class="indent1">Cyclophosphamide</td> <td class="highlight_red_text"> <p class="large_checkmark">××</p> Stop 3 months prior to conception </td> <td class="highlight_lght_green_text"> <p class="large_checkmark">+</p> Life-/organ-threatening disease in second and third trimesters </td> <td class="highlight_red_text"><span class="large_checkmark">××</span></td> </tr> <tr> <td class="indent1">Thalidomide</td> <td class="highlight_red_text"> <p class="large_checkmark">××</p> Stop 1-3 months prior to conception </td> <td class="highlight_red_text"><span class="large_checkmark">××</span></td> <td class="highlight_red_text"><span class="large_checkmark">××</span></td> </tr> <tr> <td class="indent1">Tofacitinib, apremilast, baricitinib</td> <td class="highlight_lght_gray_text" colspan="3">Unable to determine due to lack of data; small molecular size suggests transfer across the placenta and into breast milk</td> </tr> </tbody></table></div><div class="graphic_reference">From: Sammaritano LR, Bermas BL, Chakravarty EE, et al. 2020 American College of Rheumatology Guideline for the management of reproductive health in rheumatic and musculoskeletal diseases. Arthritis Care Res (Hoboken) 2020; 72:461. <a href="https://acrjournals.onlinelibrary.wiley.com/doi/10.1002/acr.24130" target="_blank">https://acrjournals.onlinelibrary.wiley.com/doi/10.1002/acr.24130</a>. Copyright © 2020 American College of Rheumatology. Reproduced with permission of John Wiley &amp; Sons Inc. This image has been provided by or is owned by Wiley. Further permission is needed before it can be downloaded to PowerPoint, printed, shared or emailed. Please contact Wiley's permissions department either via email: <a href="/cdn-cgi/l/email-protection#4c3c293e21253f3f2523223f0c3b25202935622f2321"><span class="__cf_email__" data-cfemail="770712051a1e04041e18190437001e1b120e5914181a">[email protected]</span></a> or use the RightsLink service by clicking on the 'Request Permission' link accompanying this article on Wiley Online Library (<a href="https://onlinelibrary.wiley.com/" target="_blank">https://onlinelibrary.wiley.com/</a>).</div><div id="graphicVersion">Graphic 141979 Version 2.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
